Single Injection Partially Restores Vision in Age-Related Macular Degeneration After 3 Years
A stem cell therapy for geographic atrophy showed sustained vision gains and retinal repair three years after a single injection in a Phase 1/2a trial.
Summary
Geographic atrophy is a leading cause of blindness in older adults, caused by the death of retinal pigment epithelium (RPE) cells. Lineage Cell Therapeutics reported 3-year results for OpRegen, a stem cell-derived RPE therapy injected beneath the retina. In the best-performing group of 10 patients, vision improved by an average of 6.2 letters on a standard eye chart, with a subgroup of 5 patients gaining 9.0 letters. Imaging showed partial regrowth of retinal structures, including the return of an RPE layer and photoreceptor features, in treated eyes — while untreated eyes continued to deteriorate. These results suggest a single treatment may durably slow or partially reverse this blinding age-related disease, with a larger optimization trial now enrolling.
Detailed Summary
Geographic atrophy (GA) is an advanced, irreversible form of age-related macular degeneration (AMD) — one of the most common causes of vision loss in people over 60. It occurs when retinal pigment epithelium (RPE) cells die, stripping photoreceptors of their support and causing progressive central vision loss. Until recently, no treatment could restore lost tissue. OpRegen represents a fundamentally different approach: transplanting lab-grown RPE cells derived from stem cells directly beneath the retina in a single surgical procedure.
At the Foundation Fighting Blindness summit in 2026, Lineage reported 36-month outcomes from 10 patients in Cohort 4 of their Phase 1/2a trial. The mean vision gain was +6.2 ETDRS letters — a clinically meaningful improvement on the standard eye chart. A subgroup of five patients who received broader retinal coverage with OpRegen gained an average of +9.0 letters, suggesting that delivery precision matters significantly for outcomes.
Beyond vision scores, structural imaging told a compelling story. Optical coherence tomography showed that treated eyes maintained and even expanded RPE-complex area by 1.9 mm² on average, while untreated fellow eyes lost 3.8 mm² over the same period. Imaging also revealed partial reappearance of an RPE layer and photoreceptor-associated features — signs of genuine tissue restoration rather than just stabilization.
These findings are notable because GA has historically been considered irreversible. A single subretinal injection producing durable anatomical and functional improvements over three years, if confirmed in larger trials, would represent a paradigm shift in treating age-related eye disease.
Important caveats apply. This is a small Phase 1/2a trial (24 patients total, 10 with 3-year data), designed primarily for safety and early efficacy signals. Results are not yet peer-reviewed in full. The ongoing GAlette Phase 2a surgical optimization study will provide more rigorous evidence on efficacy, optimal dosing, and delivery technique before any clinical adoption.
Key Findings
- Patients receiving OpRegen gained an average of 6.2 ETDRS vision letters at 3 years after a single injection.
- A subgroup with broader retinal coverage gained 9.0 letters, highlighting the importance of delivery precision.
- Treated eyes showed RPE tissue growth (+1.9 mm²) while untreated fellow eyes declined (−3.8 mm²).
- Imaging revealed partial regrowth of RPE layer and photoreceptor features — suggesting true tissue restoration.
- A larger Phase 2a surgical optimization trial (GAlette) is now enrolling to confirm and refine these results.
Methodology
This is a news report summarizing conference-presented data from a Phase 1/2a open-label clinical trial (NCT02286089) with 24 enrolled patients. The source, Longevity.Technology, is a credible longevity-focused outlet; however, the underlying data has not yet been published in a peer-reviewed journal. Evidence basis is preliminary clinical trial data presented at an industry summit.
Study Limitations
Trial size is very small (n=10 with 3-year follow-up), limiting statistical power and generalizability. Data was presented at a conference and has not been peer-reviewed or published in full. Long-term safety, durability beyond 3 years, and optimal patient selection criteria remain to be established in larger trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.